 Tumor Stem Cell Assay
"Tumor Stem Cell Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
| Descriptor ID |
D014410
|
| MeSH Number(s) |
E01.370.225.500.383.910 E01.370.225.500.388.930 E05.200.500.383.910 E05.200.500.388.930 E05.242.383.910 E05.242.417.500 E05.337.550.200.800
|
| Concept/Terms |
Tumor Stem Cell Assay- Tumor Stem Cell Assay
- Colony Forming Units Assay, Tumor
- Neoplasm Stem Cell Assay
- Stem Cell Assay, Tumor
- Clonogenic Cell Assay, Tumor
- Colony-Forming Units Assay, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Stem Cell Assay".
Below are MeSH descriptors whose meaning is more specific than "Tumor Stem Cell Assay".
This graph shows the total number of publications written about "Tumor Stem Cell Assay" by people in this website by year, and whether "Tumor Stem Cell Assay" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2012 | 0 | 2 | 2 | | 2014 | 0 | 2 | 2 | | 2015 | 1 | 2 | 3 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Stem Cell Assay" by people in Profiles.
-
Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Sci Rep. 2021 06 23; 11(1):13158.
-
Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, Ganesan S. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. J Thorac Oncol. 2019 11; 14(11):1982-1988.
-
Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Rep. 2017 03 28; 18(13):3204-3218.
-
Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep. 2016 12 12; 6:38792.
-
Aguado BA, Caffe JR, Nanavati D, Rao SS, Bushnell GG, Azarin SM, Shea LD. Extracellular matrix mediators of metastatic cell colonization characterized using scaffold mimics of the pre-metastatic niche. Acta Biomater. 2016 Mar; 33:13-24.
-
Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR, Crooks PA. Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. J Med Chem. 2015 Nov 25; 58(22):8896-906.
-
Kahlert UD, Suwala AK, Koch K, Natsumeda M, Orr BA, Hayashi M, Maciaczyk J, Eberhart CG. Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. J Neuropathol Exp Neurol. 2015 Sep; 74(9):889-900.
-
Xiong W, Knox AJ, Xu M, Kiseljak-Vassiliades K, Colgan SP, Brodsky KS, Kleinschmidt-Demasters BK, Lillehei KO, Wierman ME. Mammalian Ste20-like kinase 4 promotes pituitary cell proliferation and survival under hypoxia. Mol Endocrinol. 2015 Mar; 29(3):460-72.
-
Tilley C, Deep G, Agarwal C, Wempe MF, Biedermann D, Valentov? K, Kren V, Agarwal R. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation. Mol Carcinog. 2016 Jan; 55(1):3-14.
-
Cummings CT, Linger RM, Cohen RA, Sather S, Kirkpatrick GD, Davies KD, DeRyckere D, Earp HS, Graham DK. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget. 2014 Nov 15; 5(21):10434-45.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|